Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; purified talc; magnesium stearate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

rad data australia pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; purified talc; magnesium stearate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - quinine dihydrochloride, quantity: 60 mg/ml - injection, solution - excipient ingredients: water for injections - indications as at 1 january 1991 : acute treatment of malaria. it may also be used in the treatment of babesiosis in conjunction with clindamycin.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - busulfan, quantity: 60 mg - injection, solution - excipient ingredients: dimethylacetamide; macrogol 400 - busulfan injection is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - fluconazole sandoz injection is indicated in adults and children for the following conditions only if fluconazole can not be administered orally. for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral and intravenous therapy has a less favourable ratio of benefits to risks. (see adverse effects.)

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - melatonin, quantity: 3 mg - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; sorbitol; magnesium stearate; colloidal anhydrous silica - melatonin may help people who experiencing occasional sleeplessness, those with jet lag, or anyone seeking to improve their quality of rest due to sleep disturbance

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; purified talc; magnesium stearate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

energique, inc. - melatonin (unii: jl5dk93rcl) (melatonin - unii:jl5dk93rcl) - may temporarily relieve symptoms associated with reactions to melatonin such as sleeplessness.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve symptoms associated with reactions to melatonin such as sleeplessness.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Izrael - angleščina - Ministry of Health

mip veterinaria ltd - melatonin - implant for injection - melatonin 18 mg - improvment of the reproductive performance of the sheep.

Namibija - angleščina - Namibia Medicines Regulatory Council

trinity pharma (pty) ltd - melatonin - prolonged release tablet - eacch prolonged release tablet contains melatonin 2mg